KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics Inc (KROS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-04 | C+ (2.7) | D (1.3) | C+ (2.8) | C (2.4) | C- (1.9) | C (2.2) |
| 2026-08-03 | C+ (2.7) | C- (2.0) | C+ (2.7) | C (2.4) | C- (2.0) | C (2.4) |
| 2026-08-02 | C+ (2.7) | C- (2.0) | C+ (2.7) | C (2.4) | C- (1.9) | C (2.4) |
| 2026-07-29 | C+ (2.6) | C+ (2.5) | D+ (1.8) | D (1.2) | D+ (1.5) | C- (1.9) |